Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight The non-small cell lung cancer clinical trial analysis report ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...

The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...

Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

Asia-Pacific promises rapid growth, while increasing tobacco use and investments in oncology centers drive demand for ...